Skip to main content
Premium Trial:

Request an Annual Quote

FDA Says CLIA Labs Can Use Cepheid's Xpert GBS Test in POC Setting

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has said CLIA labs can use Cepheid’s Xpert Group B Streptococcus test, Cepheid said today.
 
Last month the agency cleared the test as an in vitro diagnostic. The recent move, which categorizes the Xpert test as "moderate complexity," means the test can be used by 27,000 additional labs.
 
Cepheid said the Xpert assay is the first amplified molecular diagnostic using real-time PCR to receive the moderate complexity CLIA categorization.
 
The test is designed to detect Group B Strep DNA in vaginal and rectal swabs in the point-of-care setting.
The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.